Mizuho Maintains Outperform on Biogen, Raises Price Target to $241

Benzinga · 08/04 18:11
Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $221 to $241.